EUVIMEDEUVIMED entdecken
Crossref

Tirzepatide in Type 2 Diabetes Mellitus: A Comprehensive Review of Its Novel Dual GIP/GLP-1 Receptor Agonism, Clinical Efficacy, Safety, and Therapeutic Potential

Maab Ahmad Abualsaud, Fatimah Adnan AlAwami, Hadi Musfer Ali Algashaneen, Nouf Adel Albelushi, Athari Saleh Alyami, Mohammed Abdulrauf ALNasseri, Duaa jassim al juman, Duaa jassim al juman, Sarah Ali ALObaid, Ali Abdulmohsen Almuhanna, Fatimah Saeed Al Mohammed, Alawiah Hashim Alshurafa und 4 weitere

INTERNATIONAL JOURNAL OF ADVANCES IN SIGNAL AND IMAGE SCIENCES · 08.10.2026 · 12 (10s) · 31-45

DOI: 10.29284/x84kd674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift INTERNATIONAL JOURNAL OF ADVANCES IN SIGNAL AND IMAGE SCIENCES, online erschienen am 08.10.2026. Verfasst von Maab Ahmad Abualsaud und 15 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tirzepatide represents a paradigm shift in the pharmacological management of type 2 diabetes mellitus (T2DM), introducing the first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide demonstrates superior glycemic control compared to existing therapies, with HbA1c reductions ranging from 1.87% to 3.02% and substantial weight loss of 5.4 to 12.9 kg in T2DM patients. Its dual receptor agonism enhances beta-cell function, improves insulin sensitivity, and addresses multiple cardiometabolic risk factors. The safety profile is favorable, with predominantly mild-to-moderate gastrointestinal adverse events, low hypoglycemia risk, and promising cardiovascular outcomes. This review examines tirzepatide's molecular mechanisms, clinical efficacy across diverse patient populations, safety considerations, and broader therapeutic potential beyond glycemic control, positioning it as a transformative agent in metabolic disease management.

Zitieren

APA

Abualsaud, M. A., AlAwami, F. A., Algashaneen, H. M. A., Albelushi, N. A., Alyami, A. S., ALNasseri, M. A., juman, D. J. A., juman, D. J. A., ALObaid, S. A., Almuhanna, A. A., Mohammed, F. S. A., Alshurafa, A. H., Al-Farhan, A. T., Alsaif, H. F., Abohamla, L. A., & alzahrani, S. S. (2026). Tirzepatide in Type 2 Diabetes Mellitus: A Comprehensive Review of Its Novel Dual GIP/GLP-1 Receptor Agonism, Clinical Efficacy, Safety, and Therapeutic Potential. INTERNATIONAL JOURNAL OF ADVANCES IN SIGNAL AND IMAGE SCIENCES, 12(10s), 31-45. https://doi.org/10.29284/x84kd674

Vancouver

Abualsaud MA, AlAwami FA, Algashaneen HMA, Albelushi NA, Alyami AS, ALNasseri MA, et al. Tirzepatide in Type 2 Diabetes Mellitus: A Comprehensive Review of Its Novel Dual GIP/GLP-1 Receptor Agonism, Clinical Efficacy, Safety, and Therapeutic Potential. INTERNATIONAL JOURNAL OF ADVANCES IN SIGNAL AND IMAGE SCIENCES. 2026;12(10s):31-45. doi:10.29284/x84kd674

BibTeX
@article{Abualsaud2026,
  author = {Abualsaud, Maab Ahmad and AlAwami, Fatimah Adnan and Algashaneen, Hadi Musfer Ali and Albelushi, Nouf Adel and Alyami, Athari Saleh and ALNasseri, Mohammed Abdulrauf and juman, Duaa jassim al and juman, Duaa jassim al and ALObaid, Sarah Ali and Almuhanna, Ali Abdulmohsen and Mohammed, Fatimah Saeed Al and Alshurafa, Alawiah Hashim and Al-Farhan, Abdullah Twfiq and Alsaif, Hassan Fadel and Abohamla, Lama Abdulaziz and alzahrani, Salman Saad},
  title = {Tirzepatide in Type 2 Diabetes Mellitus: A Comprehensive Review of Its Novel Dual GIP/GLP-1 Receptor Agonism, Clinical Efficacy, Safety, and Therapeutic Potential},
  journal = {INTERNATIONAL JOURNAL OF ADVANCES IN SIGNAL AND IMAGE SCIENCES},
  year = {2026},
  volume = {12},
  number = {10s},
  pages = {31--45},
  doi = {10.29284/x84kd674}
}
Kostenlos starten →